Preface -- Introduction of Druggable Lipid Signaling Pathway -- Biosynthetic Enzymes of Membrane Glycerophospholipid Diversity as Therapeutic Targets for Drug Development -- Druggable Prostanoid Pathway -- Targeting Leukotrienes as a Therapeutic Strategy to Prevent Comorbidities Associated with Metabolic Stress -- Epoxy Fatty Acids are Promising Targets for Treatment of Pain, Cardiovascular Disease and Other Indications Characterized by Mitochondrial Dysfunction, Endoplasmic Stress and Inflammation -- Druggable Sphingolipid Pathway -- Druggable Lysophospholipid Pathway -- Druggable targets in endocannabinoid signaling -- Drugging the phosphoinositide 3-kinase (PI3K) and phosphatidylinositol 4-kinase (PI4K) family of enzymes for treatment of cancer, immune disorders, and viral/parasitic infections -- Druggable Lipid GPCRs: Past, Present, and Prospects

This edited work presents a series of reviews focusing on Druggable Lipid Signaling Pathways. It enables researchers in both academic institutions and industry as well as physicians to understand historical aspects of lipid signaling and future directions of drug discovery targeting lipid signaling pathways. This book provides 9 pathways including acyltransferases, prostanoids, leukotrienes, epoxy fatty acids, sphingolipids, lysophospholipids, endocannabinoids, phosphoinositides, and lipid GPCRs. Readers will discover the importance of each lipid signaling pathway that contributes to broad range of diseases including neurological and neuropsychiatric diseases, pain, metabolic syndromes, cardiovascular diseases, cancer, dermatological diseases, fibrosis, inflammation, etc. Also, readers will recognize that many drugs targeting lipid signaling have been clinically used. Drugs currently under development are also discussed in each chapter, which includes some information about clinical trials and strategic drug designs